TABLE 1

Clinical characteristics of the examined Danish white individuals

Glucose-tolerant subjects from the Inter99 cohortSubjects with IFG from the Inter99 cohortSubjects with IGT from the Inter99 cohortType 2 diabetic patients from the Inter99 cohortGlucose-tolerant subjects from the Steno Diabetes CenterType 2 diabetic patients from the Steno Diabetes Center
n (men/women)4,441 (2,067/2,374)495 (365/130)684 (335/349)345 (213/132)332 (157/175)1,063 (638/417)
Age at examination (years)45 ± 849 ± 748 ± 851 ± 762 ± 559 ± 11
BMI (kg/m2)25.5 ± 4.027.9 ± 4.628.1 ± 5.230.4 ± 5.726.1 ± 3.629.5 ± 5.2
Fasting plasma glucose (mmol/l)5.3 ± 0.46.3 ± 0.25.7 ± 0.58.1 ± 3.05.1 ± 0.49.8 ± 3.5
HbA1c (%)7.0 ± 1.68.1 ± 1.6
Mean age at diagnosis (years)45 ± 1053 ± 10
  • Data are means ± SD. The type 2 diabetic patients were recruited from the outpatient clinic at the Steno Diabetes Center (n = 1,063) and from the population-based Inter99 cohort established at the Research Centre for Prevention and Health (n = 345, of whom 248 were screen detected and untreated) (refs. 19,20). Subjects with NGT were ascertained from the Steno Diabetes Center and randomly recruited through the central person register or through the Inter99 cohort, and subjects with IFG and IGT were recruited from the Inter99 cohort. In the present study, type 2 diabetic patients with diabetes due to known chronic pancreatitis, hemochromatosis, severe insulin resistance, maturity-onset diabetes of the young, or maternally inherited diabetes and deafness; patients with a family history of first-degree relatives with type 1 diabetes; patients with an insulin requirement within the 1st year after diabetes diagnosis; or patients with a fasting serum C-peptide level ≤150 pmol/l at the time of recruitment were excluded from the category of clinically defined type 2 diabetes. IFG, IGT, and type 2 diabetes were diagnosed in accordance with WHO criteria (ref. 18). IFG: fasting plasma glucose concentration between 6.1 and 6.9 mmol/l and a 2-h post–glucose load plasma glucose concentration <7.8 mmol/l; IGT: fasting plasma glucose <7.0 mmol/l and 2-h plasma glucose ≥7.8 mmol/l and <11.1 mmol/l; type 2 diabetes: fasting plasma glucose ≥7.0 mmol/l and/or 2-h plasma glucose ≥11.1 mmol/l.